From Compliance to Strategic Partner: The Transformation of Regulatory Affairs in AstraZeneca Local Affiliates

The article proposes that local Regulatory Affairs should move from downstream execution of global plans to earlier, cross-functional strategic involvement, organized around three pillars: Launch Excellence, External Engagement and Advocacy, and Digitalisation and Process Optimisation. Relative to the traditional focus on dossier preparation, compliance, liaison with national authorities, and maintenance of marketing authorisations, this reframes local RA as a strategic participant across early-asset, launch, and brand planning. This is a descriptive, article-level account based on the authors' summary of transformation practice in AstraZeneca's European local MCRA teams, without quantitative data or a controlled study.

The article emphasizes a "One-Team" local-global RA culture operationalised through the MCRA Operating Model, in which local MCRA professionals are embedded in affiliate cross-functional teams while maintaining bi-directional collaboration with Global RA. This arrangement enables local insights to inform global strategy and helps ensure global decisions are implementable at the country level, in contrast to a one-way global-to-local execution chain. This is an experiential description of an organizational model based on the article's account of AstraZeneca's internal ways of working, with no reported sample size or effect measurement.

The article proposes a contribution-based measurement framework combining quantitative and qualitative indicators aligned with the three pillars and the "One-Team" model, focusing on predictability, launch readiness, environment-shaping activities, and organizational effectiveness. The framework recognizes that regulatory outcomes result from cross-functional decision making across the product lifecycle rather than from a single regulatory function's output, offering an alternative to traditional compliance metrics for tracking transformation progress. This is a conceptual framework proposal; the article does not provide applied data or validation results for the framework.

The scope of this article is the organizational transformation of AstraZeneca's local Marketing Companies Regulatory Affairs teams in Europe, aimed at regulatory affairs, medical affairs, and related cross-functional managers in the pharmaceutical industry. The three pillars, the MCRA Operating Model, and the contribution-based measurement framework can serve as references for local regulatory teams at other multinational pharmaceutical companies designing transformation paths in a similar EU regulatory environment.

Readers may still wonder how the contribution-based measurement framework selects specific indicators in practice, how data are collected, and how it coexists with existing compliance metrics; how the three pillars are adapted for local teams of different sizes or therapeutic areas; and how the "One-Team" model handles decisions when local and global objectives diverge. Because the reading scope here is summary-level, figures, specific cases, or implementation details in the article are not included in this summary and could affect judgment about the depth and operability of the transformation.